DK2661492T3 - Fremgangsmåde til fremstilling af rekombinante glykoproteiner med forhøjet kredsløbshalveringstid i pattedyrceller - Google Patents

Fremgangsmåde til fremstilling af rekombinante glykoproteiner med forhøjet kredsløbshalveringstid i pattedyrceller Download PDF

Info

Publication number
DK2661492T3
DK2661492T3 DK12731900.2T DK12731900T DK2661492T3 DK 2661492 T3 DK2661492 T3 DK 2661492T3 DK 12731900 T DK12731900 T DK 12731900T DK 2661492 T3 DK2661492 T3 DK 2661492T3
Authority
DK
Denmark
Prior art keywords
alpha2
rhubche
cho
sialic acid
bche
Prior art date
Application number
DK12731900.2T
Other languages
English (en)
Inventor
Michael J Betenbaugh
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46457991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2661492(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK2661492T3 publication Critical patent/DK2661492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01214—Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (4)

1. En isoleret pattedyrcelle omfattende en heterolog alpha2-6-sialy!transferase nukie-insyresekvens, eventuelt hvor cellen er en CHO-celle; yderligere omfattende en nukle-insyresekvens som reducerer ekspression af eller inaktivering af et alpha2-Ssialyltransferasegen; eller yderligere omfattende midlerne til knock-out af alpha2-3 sialyltransferasegenet,
2. Celle ifølge krav 1, hvor nukleinsyresekvensen som reducerer ekspression af eller inaktivering af alpha2-3sialyltransferasegenet eller midlerne til knock-out af alpha2-3 sialyltransferasegenet er udvalgt blandt gruppen bestående af antisense, siRNA, miRNA og en zinkfinger nuklease.
3. Celle ifølge krav 1 eller 2, hvor alpha2-3sialytransferasegenet er udvalgt blandt St3gall St3gal2, St3gal3, St3gal4, St3gal5, St3gal6-genet og en kombination deraf.
4. Fremgangsmåde til biosyntese af et alfa2-6-rigt glykoprotein omfattende dyrkning af en celle ifølge krav 1 under betingelser for at co-ekspiimere en nukleinsyresekvens som koder for et peptid eller protein, yderligere omfatter inhibering af ekspression af alpha2-3-sialyltransferase.
DK12731900.2T 2011-01-06 2012-01-06 Fremgangsmåde til fremstilling af rekombinante glykoproteiner med forhøjet kredsløbshalveringstid i pattedyrceller DK2661492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430256P 2011-01-06 2011-01-06
PCT/US2012/020535 WO2012094627A2 (en) 2011-01-06 2012-01-06 Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells

Publications (1)

Publication Number Publication Date
DK2661492T3 true DK2661492T3 (da) 2018-01-15

Family

ID=46457991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12731900.2T DK2661492T3 (da) 2011-01-06 2012-01-06 Fremgangsmåde til fremstilling af rekombinante glykoproteiner med forhøjet kredsløbshalveringstid i pattedyrceller

Country Status (10)

Country Link
US (2) US20130243744A1 (da)
EP (1) EP2661492B1 (da)
CN (2) CN107267459A (da)
AU (1) AU2012204241A1 (da)
BR (1) BR112013016447A2 (da)
CA (1) CA2817765A1 (da)
DK (1) DK2661492T3 (da)
MX (1) MX2013006234A (da)
SG (1) SG190260A1 (da)
WO (1) WO2012094627A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
BR112014016614B1 (pt) 2012-01-11 2022-02-01 Sigma-Aldrich Co. Llc Métodos para produzir uma célula deficiente em manosil (alfa-1,3-)-glicoproteína beta-1,2- nacetilglucosa-miniltransferase i (mgat1) e produzir uma proteína recombinante apresentando um ou mais resíduos de manose terminal
BR112016020287B1 (pt) * 2014-03-04 2022-06-28 Sigma-Aldrich Co. Llc Uso de uma linhagem celular de ovário de hamster chinês (cho) geneticamente modificada, composição e métodos para reduzir o risco de contaminação viral de um sistema de produção biológico e para reduzir ou prevenir a contaminação viral de um produto de proteína recombinante
WO2015142679A1 (en) 2014-03-16 2015-09-24 Yvonne Rosenberg Production of highly thermally stable recombinant cholinesterases for the detection, detoxification and decontamination of organophosphorus compounds
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
RS65665B1 (sr) * 2014-12-01 2024-07-31 Ferring Bv Selektivne kompozicije inhibitora il-6-trans-signalizacije
EP3226888B1 (en) 2014-12-01 2021-04-21 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
ES3003873T3 (en) * 2014-12-12 2025-03-11 Univ Copenhagen N-glycosylation
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
US20190211319A1 (en) * 2016-09-13 2019-07-11 Bayer Healthcare Llc FACTOR VIIa GLYCOFORMS
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
EP3570871B1 (en) * 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
CN108659095A (zh) * 2018-05-18 2018-10-16 上海药明生物技术有限公司 一种使唾液酸含量稳定的方法
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
WO2020163804A1 (en) * 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
EP4093415A1 (en) 2020-01-24 2022-11-30 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized na
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN117587020B (zh) * 2024-01-18 2024-04-02 中国人民解放军东部战区总医院 抑制ST3GAL1基因表达的shRNA及其应用
CN118755805A (zh) * 2024-09-06 2024-10-11 天津舍为斯生物技术有限公司 一种唾液酸化酶qPCR芯片及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204431B1 (en) * 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
WO2003061562A2 (en) * 2001-11-14 2003-07-31 Rosenberg Yvonne J Production of recombinant therapeutic bioscavengers against chemical and biological agents
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
US20070111279A1 (en) * 2002-11-13 2007-05-17 Procell, Inc. Production of recombinant therapeutic bioscavengers against chemical and biological agents
US8540992B2 (en) * 2006-12-28 2013-09-24 Michael Naso Methods and vectors for generating asialylated immunoglobulins
CA2702120C (en) * 2007-10-12 2016-05-17 Sigma Aldrich Co. Compositions and methods for improved glycoprotein sialylation
NZ593816A (en) * 2009-01-22 2012-11-30 Momenta Pharmaceuticals Inc Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells

Also Published As

Publication number Publication date
MX2013006234A (es) 2013-08-01
BR112013016447A2 (pt) 2019-09-24
AU2012204241A1 (en) 2013-06-06
US20170159095A1 (en) 2017-06-08
EP2661492A4 (en) 2015-04-15
EP2661492B1 (en) 2017-10-04
US20130243744A1 (en) 2013-09-19
CA2817765A1 (en) 2012-07-12
WO2012094627A3 (en) 2012-10-04
CN103221537A (zh) 2013-07-24
SG190260A1 (en) 2013-06-28
CN107267459A (zh) 2017-10-20
WO2012094627A2 (en) 2012-07-12
EP2661492A2 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
EP2661492B1 (en) Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
DK2533834T3 (da) Medikamentafgivelsesindretning
US6949372B2 (en) Engineering intracellular sialylation pathways
Wang et al. Glycoengineering of CHO cells to improve product quality
US12325871B2 (en) Lysosomal enzymes modified by cell based glycoengineering
US20110207214A1 (en) Novel tools for the production of glycosylated proteins in host cells
EP2802654B1 (en) Production of recombinant proteins with simple glycoforms
EP3230438A2 (en) N-glycosylation
CA2363297C (en) Engineering intracellular sialylation pathways
WO2011134643A1 (en) Improved glycosylation of proteins in host cells
KR102564610B1 (ko) N- 및 o-글리코실화 패턴이 변이된 당단백질을 생성하는 세포 및 그의 방법 및 용도
EP3570871B1 (en) Method for in vitro glycoengineering of an erythropoiesis stimulating protein
US20250154476A1 (en) Improved heparan sulfate and methods of making the same
WO2001042492A1 (en) Engineering intracellular sialylation pathways
Gua Structure-functional relationship study of glycosyltransferases
Buettner Using Metabolic and Genetic Engineering to Develop Novel Cell Platforms for the Production of Recombinant Glycoproteins with Enhanced Pharmacokinetic Properties
Viswanathan A study of sialylation pathways in insects and engineered insect cell lines
Mrázek α-N-Acetylgalactosaminidase as a tools in the synthesis of complex oligosaccharide immune stimulators
Kaloo Glycosylation of Carbohydrates by Glycosyltransferases
EP2563902A1 (en) Improved glycosylation of proteins in host cells